Andy Cooke

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew et al. · Molecular Cancer Therapeutics · 2011 · 200 citations

Calmodulin antagonists of improved potency and specificity for use in the study of calmodulin biochemistry

Sheila MacNeil, Martin Griffin, Andy Cooke et al. · Biochemical Pharmacology · 1988 · 50 citations

Molecular Pharmacology, Medicinal Chemistry, Improved Potency +12

Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics

Meizhong Jin, Brenda A. Petronella, Andy Cooke et al. · ACS Medicinal Chemistry Letters · 2013 · 17 citations · Full text

Small Molecule Inhibitors, Insulin Signaling, Compound 2 +17

Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy

Meizhong Jin, Andrew Kleinberg, Andy Cooke et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 16 citations · Full text

Medicinal Chemistry, Diabetes, Pharmacology +9

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases

Arno G. Steinig, An‐Hu Li, Jing Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 15 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +11